依达拉奉治疗急性脑梗塞效果评价

目的观察依达拉奉治疗急性脑梗塞的临床效果及安全性。方法选择急性脑梗塞患者68例,随机分为依达拉奉治疗组和对照组。两组在常规治疗基础上,治疗组静脉滴注依达拉奉30mg/次,2次/天,共14天,治疗前后定期对患者进行改良爱丁堡-斯堪的那维亚量表(SSS)及日常生活能力(ADL)的评定。结果治疗7天及14天后治疗组SSS评分及ADL评定与对照组比较差异有显著性(P<0.05或0.01)。治疗组治疗前后SSS评分及ADL评定差异有高度显著性(P<0.01)。治疗组无不良反应。结论依达拉奉治疗急性脑梗塞是有效安全的。

Clinical efficacy of Edaravone in acute cerebral infarction

Objective To assess the clinical efficacy and safety of Edaravone in treatment of acute cerebral infarction.Methods Sixty-eight patients with acute cerebral infarction enrolled in this study were randomly allocated to Edaravone group and control group.Besides receiving traditional therapy,the Edaravone group received i.v.Edaravone 30 mg,twice a day for 14 days.The therapy of the control group was similar to those of Edaravone group except for Edaravone.The patients' condition was evaluated by using Scandinavian Stroke Scale(SSS) and activities of daily living(ADL) before treatment and on days 7 and 14 after treatment.Results 7 and 14 days after treatment, by comparison with the control group,an improved SSS and ADL had been obtained in the Edaravone group,there were statistically significant differences(P<0.05 or 0.01).In Edaravone group, by comparison with before treatment,the SSS and ADL were improved after treatment,there were statistically significant differences(P<0.01).No side effect in the Edaravone group.Conclusion Edaravone is effective and safe in treatment of acute cerebral infarction.